SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Le coin des francophones -- Ignore unavailable to you. Want to Upgrade?


To: faro who wrote (22163)7/27/2000 10:43:16 AM
From: pallmer  Read Replies (1) | Respond to of 77509
 
Pour ceux qui suivent DAX-T ou DRAX.

DJ Taro Pharm/Fluocinonide-2: Seller Is Draxis Health >TARO

HAWTHORNE, N.Y. (Dow Jones)--Taro Pharmaceutical Industries Ltd.'s (TARO) Taro
Pharmaceuticals North America Inc. unit acquired the U.S. Abbreviated New Drug
Application, or ANDA, for Fluocinonide Emollient Cream USP, 0.05% and the
Canadian Abbreviated New Drug Submission, or ANDS, to Tiamol Fluocinonide
Emollient Cream USP 0.05% in Canada.
The products were acquired from Draxis Health Inc. (DRAX) for an undisclosed
sum.
In a press release Thursday, Taro said it has manufactured and distributed
Fluocinonide E Cream for the U.S. and Canadian market under a license agreement
with Draxis for more than 10 years.
Taro will continue to market Fluocinonide E Cream as part of the Fluocinonide
line, and it will support the Tiamol brand as part of its plan to launch a
branded dermatologic product line in Canada.
Company Web site: taropharma.com.
-Dorothea Degen; Dow Jones Newswires; 201-938-5400

(END) DOW JONES NEWS 07-27-00
10:34 AM- - 10 34 AM EDT 07-27-00